Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
| ▸ | RELA | Q04206 | 1/20 | 0.37 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4325420 | 1.00 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4318166 | 0.91 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13664986 | 0.91 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL4318170 | 0.91 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13664959 | 0.89 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13664985 | 0.88 | F10 (0.42) | F10SMN1; SMN2MEN1KMT2AHSD17B10 | |
| SCHEMBL13664987 | 0.88 | JAK1 (0.42) | F10SMN1; SMN2KMT2A | |
| SCHEMBL13664992 | 0.87 | SMN1; SMN2 (0.44) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13664966 | 0.87 | F10 (0.43) | F10SMN1; SMN2MEN1KMT2ATSHR | |
| SCHEMBL13664976 | 0.87 | GRM5 (0.46) | F10SMN1; SMN2MEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605158-B2 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-20 | — | — | US | disclosed |
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
| EP-1666478-A1 | CARBAMOYL-TYPE BENZOFURAN DERIVATIVES | TANABE SEIYAKU CO., LTD. (JP) | 2006-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247273-A1 | Carbamoyl-type benzofuran derivatives | F12, F2, F3 | F10 8/4885SMN1; SMN2 4587/4885MEN1 1937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.